• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Dear Colleagues,

The requirements associated with antidiabetic therapies are today much higher than in previous years. Currently, it is expected that antidiabetic drug not only will have potent glucose-lowering effect but also will be safe, especially with regard to cardiova- scular risk. It is extremely important that patients with diabetes, who have been dying from cardiovascular diseases for many years, use drugs that do not increase cardiovascular risk. Further, it would be perfect if antidiabetic drugs contributed to reducing this risk.

Since the announcement of the results of the EMPA- -REG OUTCOME study, we know that this is possible.

Empagliflozin was the first SGLT2 inhibitor for which, in addition to confirming its safety in patients with high-risk cardiovascular disease, cardiovascular risk reduction was also demonstrated. During the confe- rence of the American Diabetes Association that will be held in San Diego, USA, from 9 to 13 June 2017, the results of the CANVAS and CANVAS R studies on the next flozin will be announced, which may bring us closer to answering the question whether beneficial impact of empagliflozin on the cardiovascular system

is a class effect or is single molecule-specific. For those who will not be able to personally participate in this event, there is an opportunity to get answers to this and many other questions that may be of interest at the 6th Conference of the Journal of “Clinical Diabe- tology”, which will be held in Warsaw on 23–24 June 2017. Outstanding lecturers will also address many other topics related to the treatment of type 1 diabetes and will discuss with you whether the incretins and new basal insulin met our expectations. In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would like to draw your attention to the present-day problem of polypharmacy in elderly patients and to the original paper on the relationship between antidiabetic drugs and the risk of cancer.

As usual, I invite you not only to read but also to actively contribute to the “Clinical Diabetology” and

“Diabetologia Praktyczna” by submitting interesting papers as well as comments on the topics discussed in our journals.


Prof. Janusz Gumprecht



Powiązane dokumenty

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego

tropologii i filozofii społecznej, Tischner nie tylko ujawnił swój światopogląd (co nie było niczym zaskakującym, biorąc pod uwagę, że był duchownym katolickim), ale

Przekazywał nam też hoj- nie swoje wiadomości, choć byliśmy w wieku, kiedy na ogół nie docenia się wielu skarbów pchających się w ręce.. Na szczęście zapamiętałam zdradzone

The foregoing ruminations suggest that today’s urbanism needs the doctrine of harmonious urban development which can be formulated like this: activities bringing changes in the space

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to